首頁 > 市場調查報告書 > 製藥

循環系統

市場調查報告書

商品編碼

1550381

動靜脈瘻管設備市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、最終用途、地區和競爭細分，2019-2029F

Arteriovenous Fistula Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End-use, By Region, and Competition, 2019-2029F

出版日期: 2024年09月06日 | 出版商:

TechSci Research | 英文 187 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年全球動靜脈瘻管器械市場(AVF) 估值為3.0012 億美元，預計在預測期內將出現令人印象深刻的成長，到2029 年複合年成長率為7.25%。市場近年來經歷了顯著的成長和演變近年來，慢性腎臟病（CKD）患病率不斷上升，以及對有效血液透析治療的需求不斷增加。動靜脈內瘻管裝置在確保血液透析的有效且安全的血管通路方面發揮關鍵作用，特別是對於末期腎病變（ESRD）患者。市場的成長受到幾個關鍵因素的推動。首先，全球人口老化加劇導致 CKD 和 ESRD 發生率增加，增加了對血液透析程序的需求。動靜脈瘻管（AV 瘻管）裝置是一種醫療干預措施，用於在動脈和靜脈（通常是手臂）之間建立直接連接，為血液透析治療提供可靠的通路。血液透析是一種醫療程序，用於在人的腎臟不再正常運作時過濾血液中的廢物和多餘液體。 AV 瘻管裝置通常用於需要定期進行血液透析治療的末期腎臟病 (ESRD) 患者。動靜脈瘻管是透過手術將動脈和靜脈連接在一起形成的，通常位於前臂或上臂。這種連接會增加進入靜脈的血流量，使其更大、更耐用，以便在血液透析過程中反覆插入針頭。血流量的增加也有助於更有效地清除血液中的廢物。動靜脈內瘻管裝置為長期血管通路提供了更好的選擇，最大限度地降低了感染風險並最佳化了透析效率，這進一步推動了它們的採用。

市場概況
預測期	2025-2029
2023 年市場規模	30012萬美元
2029 年市場規模	4.445億美元
2024-2029 年複合年成長率	7.25%
成長最快的細分市場	AVF 創建設備
最大的市場	北美洲

醫療技術的進步也刺激了動靜脈內瘻管設備的創新。製造商正在開發更俱生物相容性、耐用且不易出現併發症的設備。這些創新旨在提高患者的舒適度、減少干涉頻率並延長瘻管的壽命，從而改善患者的整體治療效果。從地理上看，該市場表現出廣泛的影響力，北美、歐洲、亞太地區和其他地區都為其成長做出了貢獻。印度和中國等亞太地區發展中經濟體的醫療基礎設施和先進醫療手段顯著增加，推動了對動靜脈內瘻管設備的需求。然而，市場內部仍存在挑戰。建立瘻管所需的複雜外科手術需要熟練的醫療保健專業人員，而瘻管的成熟期也增加了複雜性。替代血管通路方法，如動靜脈移植物和中心靜脈導管，繼續使用，給動靜脈瘻管裝置市場帶來競爭。由於 CKD 盛行率不斷上升、醫療技術的進步以及醫療保健基礎設施的擴大，全球動靜脈內瘻管設備市場正在強勁成長。隨著市場的不斷發展，人們越來越重視研究和開發，旨在進一步提高這些設備的性能、耐用性和患者友善性。隨著人們越來越關注改善血液透析患者的生活品質，動靜脈瘻管設備市場可能仍然是現代腎臟病護理的重要組成部分。

主要市場促進因素

慢性腎臟病 (CKD) 盛行率上升

血液透析治療的需求不斷成長

增加醫療支出

主要市場挑戰

複雜的手術程序

瘻管成熟時間

主要市場趨勢

遠距醫療和遠端監控

研究和臨床試驗

細分市場洞察

類型洞察

區域洞察

Global Arteriovenous Fistula Devices Market (AVF) was valued at USD 300.12 million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.25% through 2029. The global arteriovenous fistula devices market has experienced significant growth and evolution in recent years, driven by the rising prevalence of chronic kidney diseases (CKD) and the increasing need for effective hemodialysis treatments. Arteriovenous fistula devices play a pivotal role in ensuring efficient and safe vascular access for hemodialysis, particularly in patients with end-stage renal disease (ESRD). The market's growth is propelled by several key factors. First, the growing aging population worldwide has contributed to an increased incidence of CKD and ESRD, thereby augmenting the demand for hemodialysis procedures. An arteriovenous fistula (AV fistula) device is a medical intervention used to create a direct connection between an artery and a vein, typically in the arm, to provide reliable access for hemodialysis treatment. Hemodialysis is a medical procedure used to filter waste and excess fluids from the blood when a person's kidneys are no longer functioning properly. The AV fistula device is commonly used in patients with end-stage renal disease (ESRD) who require regular hemodialysis treatments. The AV fistula is surgically created by connecting an artery and a vein together, usually in the forearm or upper arm. This connection causes increased blood flow into the vein, making it larger and more durable for repeated needle insertions during hemodialysis sessions. The increased blood flow also helps remove waste products from the blood more efficiently. Arteriovenous fistula devices offer a superior option for long-term vascular access, minimizing infection risks and optimizing dialysis efficiency, which has further fueled their adoption.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 300.12 Million
Market Size 2029	USD 444.50 Million
CAGR 2024-2029	7.25%
Fastest Growing Segment	AVF Creation Devices
Largest Market	North America

The advancements in medical technology have also spurred innovation in arteriovenous fistula devices. Manufacturers are developing devices that are more biocompatible, durable, and less prone to complications. These innovations aim to enhance patient comfort, reduce intervention frequency, and prolong the lifespan of the fistula, thereby improving overall patient outcomes. Geographically, the market exhibits a widespread presence, with North America, Europe, Asia Pacific, and other regions all contributing to its growth. Developing economies in Asia Pacific, such as India and China, have seen a notable increase in healthcare infrastructure and access to advanced medical treatments, driving the demand for arteriovenous fistula devices. However, challenges remain within the market. The intricate surgical procedure required for fistula creation demands skilled healthcare professionals, and the maturation period of the fistula adds to the complexity. The alternative vascular access methods, such as arteriovenous grafts and central venous catheters, continue to be utilized, presenting competition to the arteriovenous fistula devices market. The global arteriovenous fistula devices market is witnessing robust growth due to the escalating prevalence of CKD, advancements in medical technology, and expanding healthcare infrastructures. As the market continues to evolve, there is a growing emphasis on research and development, aiming to further enhance the performance, durability, and patient-friendliness of these devices. With an ever-increasing focus on improving the quality of life for patients undergoing hemodialysis, the arteriovenous fistula devices market is likely to remain a crucial component of modern nephrology care.

Key Market Drivers

Rising Prevalence of Chronic Kidney Disease (CKD)

The rising prevalence of chronic kidney disease (CKD) has emerged as a significant driver shaping the global arteriovenous fistula devices market. CKD refers to the progressive and irreversible deterioration of kidney function over time, and it represents a growing public health concern worldwide. This escalating prevalence has profound implications for the demand and adoption of arteriovenous fistula devices. Several factors contribute to the increasing prevalence of CKD. Demographic shifts, including an aging global population, play a pivotal role. As individuals age, their kidneys naturally undergo changes, and older adults are more susceptible to kidney dysfunction. This demographic trend has led to a higher incidence of CKD cases, consequently driving the demand for renal replacement therapies such as hemodialysis. Secondly, the global surge in non-communicable diseases, particularly diabetes and hypertension, has amplified CKD rates. Both conditions are leading causes of kidney damage, with diabetes causing diabetic nephropathy and hypertension leading to hypertensive nephropathy. These comorbidities result in a higher likelihood of kidney function decline, necessitating renal replacement therapies like hemodialysis, which often requires arteriovenous fistula devices. The lifestyle factors, including unhealthy diets and sedentary behavior, contribute to the rise in CKD cases. Poor dietary choices and inadequate physical activity can contribute to obesity, diabetes, and hypertension, all of which increase the risk of kidney damage and CKD development. The increasing global awareness of CKD and its impact on public health has led to improved screening and early detection efforts. As more cases of CKD are identified in their early stages, the need for effective and reliable vascular access for hemodialysis, such as arteriovenous fistula devices, becomes even more pronounced.

Growing Need for Hemodialysis Treatment

The growing need for hemodialysis treatment has become a significant driving force in shaping the global arteriovenous fistula devices market. Hemodialysis is a life-sustaining medical procedure used to filter waste products and excess fluids from the blood when the kidneys fail to adequately perform these functions. This escalating demand for hemodialysis has direct implications for the adoption and utilization of arteriovenous fistula devices. One of the primary contributors to the increased need for hemodialysis is the rising prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD) on a global scale. As CKD progresses to its advanced stages, kidney function declines to the point where dialysis becomes essential for maintaining the body's internal balance. This has led to a growing population of patients who require regular hemodialysis sessions for survival. The changing disease patterns and lifestyle factors, such as the global surge in diabetes and hypertension, have contributed to the increase in ESRD cases. These conditions are known to accelerate kidney damage, leading to a higher likelihood of kidney function deterioration and the subsequent need for hemodialysis treatment. The availability of hemodialysis treatment has also expanded due to advances in medical infrastructure and technology. Healthcare systems in many countries have developed or improved their dialysis facilities, making this life-sustaining therapy more accessible to a larger number of patients. This, in turn, has bolstered the demand for arteriovenous fistula devices, which provide a durable and effective means of vascular access for hemodialysis. As the global population ages and the burden of chronic diseases continues to rise, the need for hemodialysis treatment is expected to further intensify. The arteriovenous fistula device market is poised to benefit from this trend as these devices offer a reliable and long-lasting solution for creating the necessary access points for hemodialysis procedures. Ensuring optimal vascular access becomes paramount to enhance patient outcomes and minimize complications, making arteriovenous fistula devices a critical component in meeting the growing need for hemodialysis treatment worldwide.

Increasing Healthcare Expenditure

The increasing healthcare expenditure across the globe has significant implications for the growth and development of the global arteriovenous fistula devices market. Healthcare expenditure encompasses the financial resources allocated to medical services, treatments, and technologies, and its upward trajectory has a direct impact on the demand for and utilization of arteriovenous fistula devices. As economies expand and healthcare systems evolve, there is a growing recognition of the importance of addressing chronic diseases and providing advanced medical interventions. Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are among the conditions that require substantial healthcare resources, including renal replacement therapies like hemodialysis. Arteriovenous fistula devices play a pivotal role in hemodialysis, serving as a reliable and durable means of vascular access. The increasing healthcare expenditure enables healthcare systems to invest in the infrastructure, facilities, and medical devices necessary for delivering quality hemodialysis care, including the adoption of arteriovenous fistula devices. The availability of financial resources enables research and development initiatives aimed at advancing medical technologies, including arteriovenous fistula devices. Manufacturers can invest in designing and producing more innovative, patient-friendly, and efficient devices that align with evolving healthcare needs and quality standards. This continuous innovation not only enhances patient comfort and safety but also contributes to the growth of the arteriovenous fistula devices market.

Key Market Challenges

Complex Surgical Procedures

Complex surgical procedures in the context of the global arteriovenous fistula devices market refer to the intricate and skill-intensive techniques involved in creating and managing arteriovenous fistulas (AVFs) for hemodialysis access. AVFs are surgically constructed connections between an artery and a vein, usually in the arm, allowing for increased blood flow and a reliable access point for hemodialysis treatment. While AVFs offer numerous benefits, the complexity of the surgical procedures can present challenges and considerations within the market. The creation of an AVF involves delicate surgical techniques that demand a high level of expertise from medical professionals, typically vascular surgeons. The surgeon must identify suitable arteries and veins, make precise incisions, and skillfully connect them to establish a functional fistula. Proper placement, appropriate vessel size, and ensuring adequate blood flow are crucial aspects of the procedure. The surgery requires precision and a deep understanding of vascular anatomy to minimize complications and optimize the chances of successful maturation. The complexity of AVF procedures can impact the broader arteriovenous fistula devices market in several ways. Healthcare providers need to ensure that their medical staff is adequately trained and experienced in performing AVF surgeries. Manufacturers of AVF devices may focus on designing tools and technologies that simplify the surgical process, reduce complications, and improve patient outcomes. The patient education about the importance of optimal vascular access and the complexities involved can enhance patient cooperation and understanding.

Fistula Maturation Time

Fistula maturation time is a critical factor in the context of the global arteriovenous fistula devices market, referring to the period required for an arteriovenous fistula (AVF) to fully develop and become suitable for use in hemodialysis. Hemodialysis is a life-saving medical procedure that involves removing waste products and excess fluids from the blood when the kidneys are unable to perform this function adequately. AVFs are surgically created connections between an artery and a vein, enabling efficient blood flow and providing a reliable access point for hemodialysis. The maturation of an AVF is a complex physiological process. After the surgical creation of the AVF, the vein gradually enlarges and strengthens, adapting to the increased blood flow from the connected artery. This maturation process involves the remodeling of blood vessels, the growth of new vessels (angiogenesis), and changes in vessel wall characteristics. These changes are necessary to ensure the vein can withstand repeated needle insertions during hemodialysis and provide the necessary blood flow rates for effective treatment. The time required for an AVF to mature can vary widely among individuals. On average, it may take several weeks to a few months for an AVF to reach its optimal state. However, some AVFs may mature more quickly, while others might take longer due to factors such as the patient's overall health, vascular condition, and the specific anatomical characteristics of the AVF. For the global arteriovenous fistula devices market, understanding and addressing fistula maturation time are crucial. Healthcare providers, manufacturers, and policymakers must work together to develop strategies that expedite and optimize AVF maturation. This can involve advancements in surgical techniques, post-operative care protocols, and patient education to ensure that patients receive timely and effective hemodialysis through mature AVFs. By reducing maturation times and improving the success rate of AVFs, the market can contribute to enhancing patient outcomes, reducing healthcare costs, and improving the overall quality of care for individuals with kidney disease.

Key Market Trends

Telehealth and Remote Monitoring

Telehealth and remote monitoring are innovative approaches that have been increasingly integrated into the global arteriovenous fistula devices market, transforming the way healthcare providers manage and monitor patients with arteriovenous fistulas (AVFs) for hemodialysis access. These technologies leverage digital communication to facilitate medical consultations, follow-ups, and real-time monitoring without the need for in-person visits. Telehealth involves the use of telecommunications technology to provide healthcare services and consultations remotely. In the context of the arteriovenous fistula devices market, telehealth enables healthcare professionals to connect with patients virtually, discuss their AVF progress, address concerns, and provide guidance. This approach is particularly valuable during the critical phase of AVF maturation when patients may have questions or require support. Remote monitoring extends telehealth by enabling continuous or periodic tracking of AVF-related parameters. Specialized sensors or devices can be used to collect data on blood flow, pressure, and other relevant metrics. This data is transmitted to healthcare providers for analysis, allowing them to monitor the AVF's function and detect any abnormalities or complications in real time. Remote monitoring enhances patient safety and allows for timely intervention if issues arise. Patients can receive medical guidance and support from the comfort of their homes, reducing the need for frequent clinic visits and long travel times. This is especially advantageous for patients living in remote or underserved areas. Remote monitoring enables healthcare providers to detect early signs of AVF complications, such as stenosis or thrombosis, and intervene promptly. This can prevent serious issues and potentially reduce the need for hospitalizations. Telehealth and remote monitoring empower patients to actively participate in their AVF management. Patients can learn about AVF care, track their progress, and communicate with healthcare professionals, leading to better self-management and adherence. By minimizing unnecessary in-person visits and hospitalizations, telehealth and remote monitoring have the potential to reduce healthcare costs for both patients and providers. Remote monitoring generates valuable data that healthcare providers can analyze to make informed decisions about AVF management strategies. This data-driven approach enhances the quality of care. Early detection and intervention through remote monitoring can contribute to better AVF maturation rates, fewer complications, and improved patient outcomes.

Therefore, the telehealth and remote monitoring are transformative tools in the global arteriovenous fistula devices market. By enhancing patient engagement, enabling timely interventions, and providing efficient healthcare delivery, these technologies contribute to optimizing AVF management and improving the overall quality of care for individuals undergoing hemodialysis.

Research and Clinical Trials

Research and clinical trials play a vital role in advancing the global arteriovenous fistula devices market by fostering innovation, improving patient outcomes, and enhancing the understanding of arteriovenous fistula (AVF) creation, maturation, and management. These initiatives involve systematic investigations conducted by researchers and medical professionals to explore new techniques, technologies, and approaches to optimize AVF-related procedures. Research in the arteriovenous fistula devices market encompasses a wide range of studies, including basic laboratory research, translational studies, and clinical investigations. Researchers aim to deepen their understanding of vascular physiology, AVF maturation mechanisms, and factors that influence the success or complications of AVFs. By gaining insights into these aspects, researchers can develop strategies to expedite maturation, reduce complications, and improve overall AVF functionality. Clinical trials, a subset of research, involve human participants and are conducted to evaluate the safety, efficacy, and feasibility of new interventions or medical devices. In the context of the arteriovenous fistula devices market, clinical trials might focus on testing novel device designs, surgical techniques, or post-operative care protocols. These trials provide valuable evidence-based data that can guide healthcare practices and influence the adoption of new technologies.

Segmental Insights

Type Insights

In 2023, the Arteriovenous Fistula Devices Market was dominated by the AVF creation devices segment. This is attributed de to its critical role in hemodialysis access creation. AVF creation devices facilitate the surgical formation of arteriovenous fistulas, the preferred vascular access for hemodialysis patients due to superior long-term outcomes and lower complication rates. As hemodialysis prevalence rises globally, driven by increasing incidences of renal diseases, the demand for AVF creation devices surges accordingly. The advancements in AVF creation techniques and devices, coupled with healthcare initiatives promoting AVF as the preferred access type, further bolster the dominance of this segment in the market and is predicted to continue expanding over the coming years. This is due rising prevalence of End-stage renal disease (ESRD) and the growing number of individuals requiring dialysis treatment have created a higher demand for AVF procedures. The significance of AVF creation devices lies in their essential role in addressing the increasing need for dialysis treatment. These devices facilitate efficient vascular access, thereby enhancing patient care and elevating the overall quality of life for individuals undergoing dialysis.

Regional Insights

North America accounted for the largest revenue share in 2023. This is ascribed due to advancements in technology, low cost of services, and availability of skilled workforce at a lower cost than developed economies and are anticipated to propel regional market growth. Increasing regulatory focus on quality control for manufacturing is one of the key factors expected to drive the growth over the forecast period. North America has a significant burden of kidney disease, and AVF devices play a crucial role in providing vascular access for hemodialysis.

Key Market Players

Medtronic PLC

Becton, Dickinson and Company

Teleflex Incorporated

Fresenius Medical Care AG & Co. KGaA.

B. Braun SE

Poly Medicure Ltd.

NxStage Medical, Inc.

Laminate Medical Technologies Ltd.

Report Scope:

In this report, the Global Arteriovenous Fistula Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Arteriovenous Fistula Devices Market, By Type:

Surgical Instruments
Vascular Grafts
Angioplasty Balloons
Others

Doppler Ultrasound
Pressure Monitoring Systems
Others

Central Venous Catheters
Stents
Others

Arteriovenous Fistula Devices Market, By End-Use:

Hospitals Cardiac Centers Others

Arteriovenous Fistula Devices Market, By Region:

United States
Canada
Mexico

Germany
France
United Kingdom
Italy
Spain

China
Japan
India
South Korea
Australia

Brazil
Argentina
Colombia

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Arteriovenous Fistula Devices Market.

Available Customizations:

Global Arteriovenous Fistula Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Arteriovenous Fistula Devices (AVF) Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (AVF Creation Devices, AVF Monitoring Devices, AVF Maintenance Devices)
  - 5.2.1.1. By AVF Creation Devices (Surgical Instruments, Vascular Grafts, Angioplasty Balloons, Others)
  - 5.2.1.2. By AVF Monitoring Devices (Doppler Ultrasound, Pressure Monitoring Systems, Others)
  - 5.2.1.3. By AVF Maintenance Devices (Central Venous Catheters, Stents, Others)
- 5.2.2. By End-use (Hospitals, Cardiac Centers, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2023)
5.3. Market Map

6. North America Arteriovenous Fistula Devices Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By End-use
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Arteriovenous Fistula Devices Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By End-use
- 6.3.2. Canada Arteriovenous Fistula Devices Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By End-use
- 6.3.3. Mexico Arteriovenous Fistula Devices Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By End-use

7. Europe Arteriovenous Fistula Devices Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By End-use
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Arteriovenous Fistula Devices Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By End-use
- 7.3.2. France Arteriovenous Fistula Devices Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By End-use
- 7.3.3. United Kingdom Arteriovenous Fistula Devices Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By End-use
- 7.3.4. Italy Arteriovenous Fistula Devices Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By End-use
- 7.3.5. Spain Arteriovenous Fistula Devices Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By End-use

8. Asia-Pacific Arteriovenous Fistula Devices Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By End-use
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Arteriovenous Fistula Devices Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By End-use
- 8.3.2. Japan Arteriovenous Fistula Devices Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By End-use
- 8.3.3. India Arteriovenous Fistula Devices Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By End-use
- 8.3.4. South Korea Arteriovenous Fistula Devices Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By End-use
- 8.3.5. Australia Arteriovenous Fistula Devices Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By End-use

9. South America Arteriovenous Fistula Devices Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By End-use
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Arteriovenous Fistula Devices Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By End-use
- 9.3.2. Argentina Arteriovenous Fistula Devices Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By End-use
- 9.3.3. Colombia Arteriovenous Fistula Devices Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By End-use

10. Middle East and Africa Arteriovenous Fistula Devices Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By End-use
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Arteriovenous Fistula Devices Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By End-use
- 10.3.2. Saudi Arabia Arteriovenous Fistula Devices Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By End-use
- 10.3.3. UAE Arteriovenous Fistula Devices Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By End-use

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition
12.2. Product Development
12.3. Recent Developments

13. Competitive Landscape

13.1. Medtronic plc
- 13.1.1. Business Overview
- 13.1.2. Company Snapshot
- 13.1.3. Products & Services
- 13.1.4. Financials (As Reported)
- 13.1.5. Recent Developments
- 13.1.6. Key Personnel Details
- 13.1.7. SWOT Analysis
13.2. Becton, Dickinson and Company
13.3. Teleflex Incorporated
13.4. Fresenius Medical Care AG & Co. KGaA.
13.5. B. Braun SE
13.6. Poly Medicure Ltd.
13.7. NxStage Medical, Inc.
13.8. Laminate Medical Technologies Ltd.